May 28, 2021
Prof. Takanori Teshima, Department of Hematology, Hokkaido University Graduate School of Medicine With a trio of CAR-T cell therapies now in Japan, what would be the financial impact of two new products being pitted against Novartis’ first-in-class Kymriah (tisagenlecleucel)? A...read more